Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

The Lancet · 1998 · 19.9K citations

Metabolic Syndrome, Diabetes Management, Insulin Management +9

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

New England Journal of Medicine · 2002 · 18.8K citations · Full text

Plasma Ghrelin Levels after Diet-Induced Weight Loss or Gastric Bypass Surgery

David S. Weigle, R. Scott Frayo, Patricia A. Breen et al. · New England Journal of Medicine · 2002 · 2.2K citations · Full text

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

Anne Flint, Anne Raben, Arne Astrup et al. · Journal of Clinical Investigation · 1998 · 1.4K citations · Full text

Nutrition, Promotes Satiety, Caloric Restriction +24

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Mette Zander, Sten Madsbad, Jan Lysgaard Madsen et al. · The Lancet · 2002 · 1.3K citations

Metabolic Syndrome, Diabetes Management, Glucagon-like Peptide 1 +9